1. Lim CY, Kim SH, Chuck RS, et al. Risk factors for pterygium in Korea: The Korean National Health and Nutrition Examination Survey V, 2010-2012. Medicine (Baltimore). 2015; 94:e1258.
2. Liu T, Liu Y, Xie L, et al. Progress in the pathogenesis of pterygium. Curr Eye Res. 2013; 38:1191–1197.
3. Dougherty PJ, Hardten DR, Lindstrom RL. Corneoscleral melt after pterygium surgery using a single intraoperative application of mitomycin-C. Cornea. 1996; 15:537–540.
4. Fujitani A, Hayasaka S, Shibuya Y, Noda S. Corneoscleral ulceration and corneal perforation after pterygium excision and topical mitomycin C therapy. Ophthalmologica. 1993; 207:162–164.
5. Kassir MS. Corneal perforation after excision of pterygium and use of 002% mitomycin eyedrops. J Fr Ophtalmol. 1999; 22:776–779.
6. Hagen KB, Waring GO 3rd, Johnson-Wint B. Progressive non-ulcerative paracentral keratolysis associated with elevated corneal metalloproteinases. Cornea. 1997; 16:486–492.
7. Lekhanont K, Patarakittam T, Mantachote K, et al. Progressive keratolysis with pseudopterygium associated with erythema elevatum diutinum. Ophthalmology. 2011; 118:927–933.
8. Tsai YY, Chiang CC, Yeh KT, et al. Effect of TIMP-1 and MMP in pterygium invasion. Invest Ophthalmol Vis Sci. 2010; 51:3462–3467.
9. Di Girolamo N, Chui J, Coroneo MT, Wakefield D. Pathogenesis of pterygia: role of cytokines, growth factors, and matrix metalloproteinases. Prog Retin Eye Res. 2004; 23:195–228.
10. Di Girolamo N, Wakefield D, Coroneo MT. Differential expression of matrix metalloproteinases and their tissue inhibitors at the advancing pterygium head. Invest Ophthalmol Vis Sci. 2000; 41:4142–4149.
11. Gomez DE, Alonso DF, Yoshiji H, Thorgeirsson UP. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol. 1997; 74:111–122.
12. Fukuda K, Chikama T, Nakamura M, Nishida T. Differential distribution of subchains of the basement membrane components type IV collagen and laminin among the amniotic membrane, cornea, and conjunctiva. Cornea. 1999; 18:73–79.
13. Tseng SC, Li DQ, Ma X. Suppression of transforming growth factor-beta isoforms, TGF-beta receptor type II, and myofibroblast differentiation in cultured human corneal and limbal fibroblasts by amniotic membrane matrix. J Cell Physiol. 1999; 179:325–335.
14. Kim HK, Park HS. Fibrin glue-assisted augmented amniotic membrane transplantation for the treatment of large noninfectious corneal perforations. Cornea. 2009; 28:170–176.
15. Solomon A, Meller D, Prabhasawat P, et al. Amniotic membrane grafts for nontraumatic corneal perforations, descemetoceles, and deep ulcers. Ophthalmology. 2002; 109:694–703.